According to FDA (May 2007), [[renal failure]] and [[cytopenia]]s have been reported in patients receiving deferasirox oral suspension tablets. It is approved in the [[European Union]] by the [[European Medicines Agency]] (EMA) for children 6 years and older for chronic iron overload from repeated blood transfusions.<ref>[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000670/WC500033927.pdf Exjade - deferasirox], from EMA website</ref><ref>[http://www.lancet.com/journals/lancet/article/PIIS0140-6736%2813%2960799-0/fulltext Turning a blind eye to deferasirox's toxicity? ], ''[[The Lancet]]'', Volume 381, No. 9873, p1183â€“1184, 6 April 2013</ref><ref>[http://www.ehealthme.com/q/exjade-side-effects-drug-interactions Review: Exjade side effects]</ref>
